CPA
AKBA icon

Capital Performance Advisors’s Akebia Therapeutics AKBA Stock Holding History

Capital Performance Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-68
Closed -$90 – 251
2024
Q3 		$90 Buy
+68
New +$91 ﹤0.01% 2715

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Capital Performance Advisors's AKBA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Akebia Therapeutics (AKBA) in Q4 2024, closing a stake of 68 shares — an estimated $90 sold.

Capital Performance Advisors first reported a position in AKBA in Q3 2024 and held it in 1 quarter. The position peaked at $90 in Q3 2024. 121 funds tracked by Wall St. Rank hold AKBA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Akebia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 68 Akebia Therapeutics shares in Q4 2024, an estimated $90.
  • Capital Performance Advisors first reported a position in Akebia Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Akebia Therapeutics position peaked at $90 in Q3 2024.
  • 121 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.